TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03697486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet with different composition
Description: Participants should not eat within the last 10 hours. Participants could drink mineral water up to 2 hours before intervention. Breakfast given is a milk-based formula which has to be finished within 15 minutes, and subjects could only consume 600 mL of mineral water within the next 4 hours after intervention. Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure ghrelin and PYY level. Breakfast given is adjusted to participants' energy requirement. Energy requirement is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity. Different composition of protein, carbohydrate and fat were given to each arm depends on their group.~After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet with different composition
Description: Participants should not eat within the last 10 hours. Participants could drink mineral water up to 2 hours before intervention. Breakfast given is a milk-based formula which has to be finished within 15 minutes, and subjects could only consume 600 mL of mineral water within the next 4 hours after intervention. Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure ghrelin and PYY level. Breakfast given is adjusted to participants' energy requirement. Energy requirement is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity. Different composition of protein, carbohydrate and fat were given to each arm depends on their group.~After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet with different composition
Description: Participants should not eat within the last 10 hours. Participants could drink mineral water up to 2 hours before intervention. Breakfast given is a milk-based formula which has to be finished within 15 minutes, and subjects could only consume 600 mL of mineral water within the next 4 hours after intervention. Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure ghrelin and PYY level. Breakfast given is adjusted to participants' energy requirement. Energy requirement is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity. Different composition of protein, carbohydrate and fat were given to each arm depends on their group.~After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured.
Study: NCT00083460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PS-341
Description: Arm 1 a dose of 1.0mg/m2. Arm 2 a dose of 1.3mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PS-341
Description: Arm 1 a dose of 1.0mg/m2. Arm 2 a dose of 1.3mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: In cohort 1, a dose of 50mg for cycles 2-8. Cohort 2, 100mg for cycles 2-8. Cohort 3, 150mg for cycles 2-8. Cohort 4, 200mg for cycles 2-8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: In cohort 1, a dose of 50mg for cycles 2-8. Cohort 2, 100mg for cycles 2-8. Cohort 3, 150mg for cycles 2-8. Cohort 4, 200mg for cycles 2-8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: A dose of 20mg for cylces 3-8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: A dose of 20mg for cylces 3-8.
Study: NCT00777959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus (MK8669)
Description: Three 10 mg tablets administered daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Three tablets of matching placebo to ridaforolimus administered daily for 5 consecutive days each week followed by 2 days without matching placebo and on 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: open-label ridaforolimus (MK8669)
Description: Single dose of three 10 mg tablets ridaforolimus on Day 1, and 50 mg bicalutamide once daily starting on Day 2. On Day 8, patients will begin taking three 10 mg tablets of ridaforolimus daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide once daily for 7 days each week. Treatment will continue until disease progression.
Study: NCT01476540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone.
Study: NCT01775553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: During Cycle 1, patients will receive either 20 mg/m2 on days 1,2 (if the subject has not received carfilzomib as part another clinical trial within the last 4 weeks) or 56 mg/m2 (if the subject is enrolling in the present study after progression of disease on carfilzomib within the last month - for example subjects enrolled in CMAP compassionate use carfilzomib). Thereafter, all subjects will receive 56 mg/m2 for the remaining doses given Cycle 1 Day 8 onwards. Each cycle is 28 days.
Study: NCT03225248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UI05MSP015CT
Description: UI05MSP015CT and Placebo of Gasmotin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gasmotin
Description: Placebo of UI05MSP015CT and Gasmotin
Study: NCT01460069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo pens contain saline and are administered in the same way and volume as (liraglutide) Victoza. The placebo pens are specially prepared for this study and will be used in the study only.
Study: NCT00705874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGC-11047 and gemcitabine
Description: Gemcitabine: (Closed to enrollment) 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle. CGC-11047 will only be given on days 1 and 15 of each cycle and will start at dose level -1 (50 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGC-11047 and docetaxel
Description: Docetaxel: (Closed to enrollment) 75 mg/m2 administered IV over 60 minutes every 21 days. CGC-11047 will be administered only on Day 1 of each 21-day cycle and will start at dose level -1 (50 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGC-11047 and bevacizumab
Description: Bevacizumab: 5 mg/kg administered IV once every 14 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGC-11047 and erlotinib
Description: Erlotinib: 150 mg taken orally every day of each 28-day cycle. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGC-11047 and cisplatin
Description: Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGC-11047 and 5-flurouracil / leucovorin
Description: 5-Flurouracil / Leucovorin: Leucovorin 500 mg/m2 IV over 2 hours with 5 - FU 500 mg/m2 IV bolus starting 1 hour into leucovorin infusion weekly for 6 wks, repeated every 56 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGC-11047 and sunitinib
Description: Sunitinib: 50 mg orally once daily, 4 weeks on treatment followed by 2 weeks off (42 day cycle). CGC-11047 will be administered on Days 1 and 8 of a 21 day cycle.
Study: NCT01404650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: AUY922: 70 mg/m2 IV over 60 minutes on Days 1, 8, and 15 of each cycle. Treatment cycles will be repeated every 21 days. Patients will be evaluated for response at 6 and 12 weeks and then every 9 weeks (i.e., every 3 cycles) thereafter. Patients may continue treatment until evidence of disease progression.
Study: NCT03940079

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: computer-based cognitive game (including 3 training tasks)
Description: First task was short-term memory training. Participants were instructed to memorize different colored circles with ordinal numbers which would disappear later. They triggered correct colored sensor in sequence according to their memory.~Second task was divided attention training. Different colored circles with ordinal numbers would not disappear this time.The participants should trigger correct colored sensor according to their sequence.~Third task was inhibitory function training. There were red and green lights, just like the traffic light, hung up at the upper left of the scene. Red light represented prohibition of triggering the colored sensor, while green light urged to trigger it. Yellow, red, blue and green circles showed up randomly and moved toward the beige region. When the circle came extremely closer to the beige region, the traffic light was randomized to lighten up red or green.The participants should judge and trigger the correct colored sensor.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: computer-based cognitive game (including 3 training tasks)
Description: First task was short-term memory training. Participants were instructed to memorize different colored circles with ordinal numbers which would disappear later. They triggered correct colored sensor in sequence according to their memory.~Second task was divided attention training. Different colored circles with ordinal numbers would not disappear this time.The participants should trigger correct colored sensor according to their sequence.~Third task was inhibitory function training. There were red and green lights, just like the traffic light, hung up at the upper left of the scene. Red light represented prohibition of triggering the colored sensor, while green light urged to trigger it. Yellow, red, blue and green circles showed up randomly and moved toward the beige region. When the circle came extremely closer to the beige region, the traffic light was randomized to lighten up red or green.The participants should judge and trigger the correct colored sensor.
Study: NCT02830919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucosamine and chondroitin sulfate combination (Eurofarma)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine and chondroitin sulfate combination (Zodic)
Study: NCT02642211

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cataract surgery
Description: Eyes (one eye per patient) randomized to either phacoemulsification and intraocular lens insertion or small incision cataract surgery and intraocular lens insertion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cataract surgery
Description: Eyes (one eye per patient) randomized to either phacoemulsification and intraocular lens insertion or small incision cataract surgery and intraocular lens insertion
Study: NCT03115918

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic Duct Stent Placement
Description: Patients will be randomly allocated to either treatment arm to have a PD stent placed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Pancreatic Duct Stent Placement
Description: Patients will be randomly allocated to either treatment arm and not receive PD placement.
Study: NCT02972229

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 10x(3-5) Gy IMRT
Description: 10x(3-5) Gy IMRT on partial vertebral body for spinal metastases

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 10x3 Gy IMRT
Description: 10x3 Gy IMRT on whole vertebral body for spinal metastases
Study: NCT02374541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: The Autism Patient Navigator (APN) will interview families to determine system and individual barriers facing the family at each stage of the care process. The APN will help families to overcome any identified barriers through education, coaching, social support, interpretation or translation, linkage to resources (e.g., for obtaining insurance) or logistical support (e.g., scheduling appointments, providing reminders, arranging transportation), in order to ensure timely diagnostic evaluation / eligibility determination; educate the family about autism, tests and treatments; and offer psychosocial support.
Study: NCT02118519

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Mesenchymal Stem Cells
Description: Comparison of clinical outcomes of patients injected by mesenchymal stem cells only with patients injected with mesenchymal stem cells supported by platelet lysate

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Mesenchymal Stem Cells
Description: Comparison of clinical outcomes of patients injected by mesenchymal stem cells only with patients injected with mesenchymal stem cells supported by platelet lysate
Study: NCT06246747

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In clinic physical therapy
Description: Patients visit the clinic to receive traditional physical therapy treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In clinic physical therapy
Description: Patients visit the clinic to receive traditional physical therapy treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation only
Description: Patients receive remote treatment using the Wizecare platform

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation only
Description: Patients receive remote treatment using the Wizecare platform
Study: NCT00183014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Lifetime Fitness Program
Description: A series of 4 weekly 1-hour group discussion sessions that utilize attribution retraining techniques from the field of motivational psychology in combination with behavioral strategies based in social cognitive theory; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise class
Description: 1-hour exercise class aimed at increasing strength, flexibility and endurance; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise class
Description: 1-hour exercise class aimed at increasing strength, flexibility and endurance; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
Study: NCT00833443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days. The medication treatment phase is for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion
Description: Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days. The medication treatment phase is for 12 weeks.
Study: NCT00222144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec and Taxotere
Description: Gleevec 600 mg QD for 12 months Taxotere IV 30 mg/m2 on day 1, 8 and 15
Study: NCT03931226

Intervention type: DRUG
Intervention: Drug consumption
Description: number of Daily Defined Doses (DDDs) of medications prescribed and given to children in connection with the indication of the spa treatment

Intervention type: DRUG
Intervention: Drug consumption
Description: number of Daily Defined Doses (DDDs) of medications prescribed and given to children in connection with the indication of the spa treatment
Study: NCT04061109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Coagulation FVIII
Description: A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
Study: NCT03988426

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octanorm
Description: Octanorm
Study: NCT02176629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Condition virtual reality (VR) then Condition classic cognitive stimulation (CCS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Condition classic cognitive stimulation (CCS) then Condition virtual reality (VR)
Study: NCT01734824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: sc RANKL-inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: daily subcutaneous injection of teriparatide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Denosumab
Description: one subcutaneous injection denosumab placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Teriparatide
Description: daily subcutaneous placebo injection
Study: NCT05595343

Intervention type: PROCEDURE
Intervention: Laparoscopic distal pancreatectomy
Description: Comparison of performed laparoscopic distal pancreas surgery in two different surgeon groups

Intervention type: PROCEDURE
Intervention: Laparoscopic distal pancreatectomy
Description: Comparison of performed laparoscopic distal pancreas surgery in two different surgeon groups
Study: NCT04389866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM VOLUMA™ XC
Description: Injectable gel

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM VOLUMA™ XC
Description: Injectable gel
Study: NCT02663336

Intervention type: OTHER
Intervention: Comparison ABPM with OBPM
Description: No interventions
Study: NCT03661177

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sovereign nation diet
Description: We will pilot a RCT with delayed intervention to provisionally assess health impacts of consuming a diet that is 50% indigenous foods for four weeks.
Study: NCT02251496

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In between meals snacks (Snacks-group)
Description: In between meals snacks (Snacks-group): The subjects in this group will be provided with and encouraged to select in-between-meals snacks providing \~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral nutrition supplement (ONS-group)
Description: The subjects in this group will be provided with and encouraged to take two ready to drink oral nutrition supplements (ONS) daily, providing \~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
Study: NCT02525640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid
Description: Hearing aid comparison
Study: NCT02613195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen-Rich Celsior Solution
Description: Before the procedure, add hydrogen gas into Celsior solution. After harvesting the liver/kidney grafts, lavage and cold store the grafts with Hydrogen-Rich Celsior Solution.
Study: NCT04391855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol with ropivacaine
Description: A solution of tramadol 2mg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine with ropivacaine
Description: A solution of dexmedetomidine 1μg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium with ropivacaine
Description: A solution of magnesium 10 mg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine plus normal saline
Description: A solution of ropivacaine hydrochloride (10mg/ml) 100mg with 5ml of isotonic saline 0.9% mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
Study: NCT04179786

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Sci-B-Vac™
Description: Sci-B-Vac™ is a recombinant Hepatitis B vaccine, produced by SciVac Israel Ltd under good manufacturing practices (GMP). It contains the 3 surface antigens of the Hepatitis B virus: HBs, pre-S1 and pre-S2. Each 1 ml dose contains sterile 10 μg Hepatitis B virus surface antigens. It is formulated for intramuscular injection supplied in single use vials containing 1ml suspension.
Study: NCT01655238

Intervention type: OTHER
Intervention: BMI
Description: Screening guideline to assess body mass index.

Intervention type: OTHER
Intervention: BMI
Description: Screening guideline to assess body mass index.